1. Search Result
Search Result
Results for "

Caco2 cells

" in MCE Product Catalog:

22

Inhibitors & Agonists

3

Dye Reagents

1

Peptides

5

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-W009141
    1-Monopalmitin

    P-glycoprotein Cancer
    1-Monopalmitin, a bitter melon extract, inhibits the P-glycoprotein (P-gp) activity in intestinal Caco-2 cells.
  • HY-13749B
    Sitagliptin phosphate monohydrate

    MK-0431 phosphate monohydrate

    Dipeptidyl Peptidase Autophagy Metabolic Disease
    Sitagliptin phosphate monohydrate (MK-0431 phosphate monohydrate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
  • HY-13749
    Sitagliptin

    MK-0431

    Dipeptidyl Peptidase Autophagy Metabolic Disease
    Sitagliptin (MK-0431) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
  • HY-13749A
    Sitagliptin phosphate

    MK-0431 phosphate

    Dipeptidyl Peptidase Autophagy Metabolic Disease
    Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
  • HY-13749S
    (Rac)-Sitagliptin-d4 hydrochloride

    Dipeptidyl Peptidase Autophagy Metabolic Disease
    (Rac)-Sitagliptin-d4 hydrochloride is a labelled racemic Sitagliptin. Sitagliptin hydrochloride is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
  • HY-N4236
    Angelol A

    Others Others
    Angelol A is a coumarin isolated from the roots of Angelica pubescens f. biserrata, which is passive diffusion as the dominating process in Caco-2 cell monolayer model.
  • HY-13749C
    (S)-Sitagliptin phosphate

    (S)-MK-0431 phosphate

    Dipeptidyl Peptidase Autophagy Metabolic Disease
    (S)-Sitagliptin phosphate is the less active S-enantiomer of Sitagliptin phosphate. Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
  • HY-N4235
    Angelol B

    Others Inflammation/Immunology
    Angelol B is a coumarin isolated from the roots of Angelica pubescens f. biserrata, which is passive diffusion as the dominating process in Caco-2 cell monolayer model.
  • HY-14291
    Vildagliptin

    LAF237; NVP-LAF 237

    Dipeptidyl Peptidase Ferroptosis Apoptosis Metabolic Disease
    Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity.
  • HY-13749AS
    Sitagliptin-d4 phosphate

    Dipeptidyl Peptidase Autophagy Metabolic Disease
    Sitagliptin-d4 (MK-0431-d4) phosphate is the deuterium labeled Sitagliptin phosphate. Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
  • HY-14291A
    Vildagliptin dihydrate

    LAF237 dihydrate; NVP-LAF 237 dihydrate

    Dipeptidyl Peptidase Ferroptosis Apoptosis Metabolic Disease
    Vildagliptin dihydrate (LAF237 dihydrate) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin dihydrate possesses excellent oral bioavailability and potent antihyperglycemic activity.
  • HY-14291S1
    Vildagliptin-d7

    LAF237-d7; NVP-LAF 237-d7

    Dipeptidyl Peptidase Ferroptosis Apoptosis Metabolic Disease
    Vildagliptin-d7 is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity.
  • HY-N2009
    3-O-Methylgallic acid

    3,4-Dihydroxy-5-methoxybenzoic acid

    Apoptosis Cancer
    3-O-Methylgallic acid (3,4-Dihydroxy-5-methoxybenzoic acid) is an anthocyanin metabolite and has potent antioxidant capacity. 3-O-methylgallic acid inhibits Caco-2 cell proliferation with an IC50 value of 24.1 μM. 3-O-methylgallic acid also induces cell apoptosis and has anti-cancer effects.
  • HY-14291S
    Vildagliptin-d3

    LAF237-d3; NVP-LAF 237-d3

    Dipeptidyl Peptidase Ferroptosis Apoptosis Metabolic Disease
    Vildagliptin-d3 (LAF237-d3) is the deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity.
  • HY-146078
    Antimicrobial agent-1

    Bacterial Infection
    Antimicrobial agent-1 (compound 6C) possesses potent activity against TolC mutant E. coli with an MIC value of 2 μg/mL. Antimicrobial agent-1 and Colistin exhibit synergistic activity against Gram-negative bacteria. Antimicrobial agent-1 has no cytotoxicity on mammalian cell lines, with MICs > 128 μg/mL in Caco-2 and Vero cell lines.
  • HY-116788
    Lipofermata

    Bacterial Infection
    Lipofermata is a fatty acid transport protein 2 (FATP2) inhibitor. Lipofermata shows fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. Lipofermata, an analog of spiro-indoline-thadiazole, shows zinc-specific suppression of antibacterial activity. Lipofermata perturbs zinc homeostasis in E. coli K-12 with a MIC of 16 μM.
  • HY-N3121
    Pachypodol

    Others Cancer
    Pachypodol exerts antioxidant and cytoprotective effects in HepG2 cells.Pachypodol inhibits the growth of CaCo 2 colon cancer cell line in vitro(IC50 = 185.6 mM).
  • HY-146111
    IRAK4-IN-13

    IRAK Cancer
    IRAK4-IN-13 (compound 21) is a potent and selective IRAK4 inhibitor with an IC50 of 0.6 nM. IRAK4-IN-13 shows high metabolic clearance with human liver microsomes (HLM) intrinsic clearance is 96 µL/min/mg.
  • HY-146113
    IRAK4-IN-15

    IRAK Cancer
    IRAK4-IN-15 (compound 35) is a potent and selective IRAK4 inhibitor with an IC50 of 0.002 µM. IRAK4-IN-15 shows good human PK predictions with low intrinsic clearance. IRAK4-IN-15 shows great synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib. .
  • HY-146112
    IRAK4-IN-14

    IRAK Cancer
    IRAK4-IN-14 (compound 28) is a potent, selective and orally active IRAK4 inhibitor with an IC50 of 0.003 µM. IRAK4-IN-14 shows good PK parameters in rats and mouse. IRAK4-IN-14 shows synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib.
  • HY-146073
    IRAK4-IN-12

    IRAK Cancer
    IRAK4-IN-12 (compound 37) is a potent IRAK4 inhibitor with an IC50 of 0.015 µM. IRAK4-IN-12 shows cell pIRAK4 potencies with an IC50 of 0.5 µM.
  • HY-146072
    IRAK4-IN-11

    IRAK Cancer
    IRAK4-IN-11 (compound 6) is a potent IRAK4 inhibitor with an IC50 of 0.008 µM. IRAK4-IN-11 shows cell pIRAK4 potencies with an IC50 of 0.19 µM.